Bannerbild German Brest Group

GBG Forschungs GmbH – a leading breast cancer research institute

Breast cancer research – independent, academic, impartial

GBG Forschungs GmbH is an independent, impartial academic research organisation (ARO). Unlike contract research organisations (CRO), we do not provide research services purely on a contract basis. All study projects have to address an academic question which meets the requirements of the German Breast Group. Through our research, we aim to continually improve the treatment of breast cancer and the quality of the therapy available on a global basis.

Independent breast cancer research – an international leader

When conducting our breast cancer research projects, we adhere to the principles of international academic study groups. Our research institute, together with the German Breast Group’s sub-boards, creates the protocols for our studies as well as our databases and is also responsible for their evaluation and publication – always without influence from the pharmaceutical industry. Examples of our research are the neoadjuvant studies belonging to the “Gepar” trial series.

Today, GBG Forschungs GmbH has clinical data from more than 35,000 breast cancer patients at its disposal. Thanks to our expertise and experience acquired through 30 years of research, we are one of the world’s leading breast cancer research institutes.

Funding of breast cancer research

Our research projects are funded in advance via clinical trials, donations, public funding, the German Cancer Aid Organisation (Deutsche Krebshilfe) and the German Research Foundation (Deutsche Forschungsgemeinschaft). In addition, we receive funding from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung ─ BMBF) and from foundations, such as the Banss-Stiftung, the Walter-Schulz-Stiftung and the Claudia-von-Schilling-Stiftung, as well as cooperation partners from the pharmaceutical industry. Our Translational Research Division is predominantly funded by the EU, the German Federal Government and various foundations.


German Breast Group: An employer for your future. We are recruiting to expand our multidisciplinary team. Get more information about our current vacancies here.


Do you have any questions about breast cancer? In our patient guide you will find comprehensive information and links to specialized self-help resources.



  • 10.04.2019 Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients

    We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.

    Mehr ...
  • 01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.

    Mehr ...
  • 04.02.2019 ESMO Breast Cancer 2019

    ESMO Breast Cancer 2019

    ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.

    Mehr ...
  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

    Mehr ...
  • 18.01.2019 Prof. Loibl among highly cited researchers 2018

    Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd